Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 14%
Sell 29%
Strong Sell 0%

Bulls say

Novavax is a promising biotechnology company with a strong focus on developing novel vaccines for a wide range of diseases. Their Matrix-M adjuvant seems to be a key value driver, as it has shown great potential in their COVID vaccine trials and could potentially be used in other pipeline programs as well. With multiple partnerships and collaborations in place, Novavax has a strong foundation for future success and growth in the vaccines market.

Bears say

Novavax is facing several challenges that could impact its financial performance in the future. These include the limited market share for its COVID-19 vaccine Nuvaxovid among older adults, the expected decline in flu vaccination rates for those aged 50-64, and the potential competition from other companies in the flu market. Additionally, the company's partnership with Sanofi may not yield significant revenue, and the risks associated with successful development and increased vaccination rates may not materialize. This could result in lower-than-expected revenues and negatively affect the company's stock performance.

Novavax (NVAX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 29% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 7 analysts, Novavax (NVAX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.